- Parties
- Cambridge SPG · Cymbiotika · Sol-ti · BugMD
- Mandate
- Consumer growth co-investment advisory
- Selected engagements
- Sol-ti: March 2026 · BugMD: July 2026
- Continuation
- Five completed transactions, latest Cymbiotika
Situation and fit
Our relationship with Cambridge SPG spans five completed consumer-growth transactions, most recently Cymbiotika. Earlier examples include Sol-ti, a beverage business built around healthy living and glass packaging, and BugMD, a household pest-control business.
Cambridge SPG focuses on leading investment rounds. Working repeatedly with a consumer specialist gives us a closer understanding of its investment approach and the questions that matter for each new business.
The work
Our work includes co-investment advisory on Sol-ti's March 2026 Series B and BugMD's July 2026 growth equity transaction. Across the relationship, the focus is on connecting specialist consumer opportunities with capital partners whose mandates and investment approach align with the offering.
Outcome and continuation
The partnership has continued through Cymbiotika. Each new engagement brings the business and investors’ current objectives into focus, informed by the experience of working together.
Capital advisory work is conducted through MVV Capital Partners. Any co-investment participation may involve MVV Capital Management. The applicable entity and role depend on each mandate.